Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
23ME610 by 23AndMe Holding for Merkel Cell Carcinoma: Likelihood of Approval
23ME610 is under clinical development by 23AndMe Holding and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData,...
Data Insights
23ME610 by 23AndMe Holding for Metastatic Renal Cell Carcinoma: Likelihood of Approval
23ME610 is under clinical development by 23AndMe Holding and currently in Phase II for Metastatic Renal Cell Carcinoma. According to...